Incyte Corporation
Incyte Announces $2.0 Billion Share Repurchase Program
Summary
On May 12, 2024, Incyte Corporation announced its intention to repurchase up to $2.0 billion of its common stock through a modified Dutch Auction tender offer, aiming to buy back up to $1.672 billion of outstanding shares. Simultaneously, the Company entered into a stock purchase agreement with the Baker Entities, allowing them to maintain their ownership level by repurchasing up to $328.0 million of the Company's common stock. This tender offer reflects the Company's confidence in its future outlook and the strength of its commercial product portfolio.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement